H.C. Wainwright Bullish on Genmab A/S (GMAB) on Robust Sales for DARZALEX

Published on February 13, 2026 at 5:19 am by Talha Qureshi in News

Genmab A/S (NASDAQ:GMAB) is one of the High Growth International Stocks to Buy Now. On January 28, H.C. Wainwright reiterated a Buy rating on Genmab A/S (NASDAQ:GMAB) and maintained a $39 price target. The rating follows robust net sales of DARZALEX in 2025.

The company on January 21 reported a significant increase in net sales of DARZALEX in 2025. Worldwide net sales of DARZALEX reached $14.351 billion in 2025, up from $11.670 billion in 2024. More than half of the worldwide sales (around $8.266 billion) came from the US, while the remaining $6.085 billion came from the rest of the world.

Genmab does not sell the drug directly. Instead, they have licensed it exclusively to Johnson & Johnson and earn royalties on all worldwide net sales. During the first nine months of 2025 (ending September 30, 2025), Genmab A/S (NASDAQ:GMAB) received $2.219 billion in total Royalty revenue, which was up significantly from $1.802 billion in the first nine months of 2024. Management attributed the 23% year-over-year increase to higher net sales of DARZALEX and Kesimpta.

Before Johnson & Johnson reported net sales, management was anticipating full-year DARZALEX royalties to be in the range of $2.3 billion – $2.4 billion. This estimation was based on DARZALEX 2025 net sales of $13.7 billion – $14.1 billion. Since the actual net sales ($14.351 billion) exceed the top end of management’s guidance, the royalties are also expected to surpass the $2.4 billion mark.

Genmab A/S (NASDAQ:GMAB) is a Denmark-based biotechnology company that specializes in creating and developing antibody therapeutics, primarily for cancer treatment. The company co-developed blockbuster drugs like DARZALEX (for multiple myeloma), Kesimpta (for multiple sclerosis), and TEPEZZA (for thyroid eye disease), earning royalties through licenses to partners like Johnson & Johnson.

Disclosure: None. This article is originally published at Insider Monkey.